peptide elongation factor 2 has been researched along with lenalidomide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasian, M; Carmel, G; Cathers, B; Chen, R; Chopra, R; Daniel, TO; Evans, JF; Gaidarova, S; Gandhi, AK; Handa, H; Ito, T; Jackson, P; Kang, J; Karasawa, S; Lopez-Girona, A; Mahmoudi, A; Mendy, D; Miller, K; Rychak, E; Schafer, PH | 1 |
1 other study(ies) available for peptide elongation factor 2 and lenalidomide
| Article | Year |
|---|---|
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Adjuvants, Immunologic; Antineoplastic Agents; HEK293 Cells; Humans; Lenalidomide; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2012 |